Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan (LNP023) Dose-Ranging in Primary IgA Nephropathy
jRCT2080224938Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2019
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of Iptacopan in IgA nephropathy (IgAN) (5 arms), sponsored by Novartis. Primary endpoint: Change in 24-hour urine protein-to-creatinine ratio (UPCR) at Day 90. Started Nov 2019; status: completed.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2080224938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224938.